mulnitorsen (Andes-1537) / Andes Biotech - LARVOL DELTA

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov) - P1 | N=67 | Completed | Sponsor: Andes Biotechnologies | Active, not recruiting ➔ Completed

Trial completion • Cervical Cancer • Colorectal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2 • KRAS • NRAS

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov) - P1; N=67; Active, not recruiting; Sponsor: Andes Biotechnologies; Recruiting ➔ Active, not recruiting; N=139 ➔ 67; Trial completion date: Nov 2022 ➔ Apr 2022

Clinical • Enrollment change • Enrollment closed • Trial completion date • Cervical Cancer • Colorectal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2 • KRAS • MRI • NRAS

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov) - P1; N=139; Recruiting; Sponsor: Andes Biotechnologies; Trial completion date: Sep 2021 ➔ Nov 2022; Trial primary completion date: Sep 2021 ➔ Apr 2022

Clinical • Trial completion date • Trial primary completion date • Cervical Cancer • Colorectal Cancer • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2 • KRAS • MRI • NRAS

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov) - P1; N=124; Recruiting; Sponsor: Andes Biotechnologies; Trial completion date: Apr 2021 ➔ Sep 2021; Trial primary completion date: Apr 2021 ➔ Sep 2021

Clinical • Trial completion date • Trial primary completion date • Cervical Cancer • Cholangiocarcinoma • Gallbladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor • HER-2

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov) - P1; N=144; Recruiting; Sponsor: Andes Biotechnologies; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Biliary Cancer • Cervical Cancer • Cholangiocarcinoma • Colorectal Cancer • Gall Bladder Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Oncology • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Urothelial Cancer • KRAS • NRAS

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov) - P1; N=144; Active, not recruiting; Sponsor: Andes Biotechnologies; Recruiting ➔ Active, not recruiting

Enrollment closed

Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors. (PubMed, J Cancer) - "Similarly, treatment of a high-grade bladder cancer PDX with Andes-1537S resulted in a strong inhibition of tumor growth. Our results suggest that ASncmtRNAs could be potent targets for bladder cancer as adjuvant therapy."

Journal • BCL2L1 • BIRC5 • CASP3

Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor (clinicaltrials.gov) - P1; N=144; Recruiting; Sponsor: Andes Biotechnologies

Clinical • New P1 trial

The Antisense long non-coding mitochondrial RNA(AS-ncmtRNA) interference with Andes-1537 as a novel treatment for Renal carcinoma (AUA 2019) - "These results support the potential use of Andes-1537 as a novel therapy for RCC."